BBA
NRIX icon

Baker Bros. Advisors’s Nurix Therapeutics NRIX Stock Holding History

Baker Bros. Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$72.2M Hold
4,658,556
– – 0.41% 29
2025
Q4 		$88.4M Buy
4,658,556
+776,431
+20% +$11.2M 0.52% 28
2025
Q3 		$35.9M Hold
3,882,125
– – 0.26% 39
2025
Q2 		$44.2M Hold
3,882,125
– – 0.43% 27
2025
Q1 		$46.1M Hold
3,882,125
– – 0.51% 22
2024
Q4 		$73.1M Hold
3,882,125
– – 0.78% 19
2024
Q3 		$87.2M Hold
3,882,125
– – 0.9% 17
2024
Q2 		$81M Hold
3,882,125
– – 1.04% 17
2024
Q1 		$57.1M Hold
3,882,125
– – 0.72% 22
2023
Q4 		$40.1M Hold
3,882,125
– – 0.46% 27
2023
Q3 		$30.5M Hold
3,882,125
– – 0.18% 27
2023
Q2 		$38.8M Hold
3,882,125
– – 0.22% 30
2023
Q1 		$34.5M Hold
3,882,125
– – 0.19% 28
2022
Q4 		$42.6M Hold
3,882,125
– – 0.26% 26
2022
Q3 		$50.6M Hold
3,882,125
– – 0.33% 26
2022
Q2 		$49.2M Buy
3,882,125
+1,428,043
+58% +$16.2M 0.28% 24
2022
Q1 		$34.4M Hold
2,454,082
– – 0.2% 41
2021
Q4 		$71M Hold
2,454,082
– – 0.35% 26
2021
Q3 		$73.5M Hold
2,454,082
– – 0.32% 25
2021
Q2 		$65.1M Hold
2,454,082
– – 0.29% 32
2021
Q1 		$76.3M Buy
2,454,082
+665,161
+37% +$25.2M 0.33% 27
2020
Q4 		$58.8M Hold
1,788,921
– – 0.22% 30
2020
Q3 		$62.5M Buy
+1,788,921
New +$45.1M 0.25% 26

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Baker Bros. Advisors's NRIX Position: Q1 2026 in Review

Baker Bros. Advisors held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 4,658,556 shares worth $72.2M. The position accounts for 0.41% of the portfolio, ranked #29.

Baker Bros. Advisors first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $88.4M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Baker Bros. Advisors held 4,658,556 shares of Nurix Therapeutics worth $72.2M as of Q1 2026.
  • Baker Bros. Advisors left its Nurix Therapeutics share count unchanged in Q1 2026.
  • Nurix Therapeutics made up 0.41% of Baker Bros. Advisors's portfolio in Q1 2026, its #29 holding.
  • Baker Bros. Advisors first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Baker Bros. Advisors's Nurix Therapeutics position peaked at $88.4M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.